IceCure CFO granted 400,000 RSUs

IceCure Medical Ltd.’s Chief Financial Officer, Peleg Meir, filed an initial ownership report showing 400,000 restricted share units (RSUs) granted on May 17, 2026.

Rhea-AI Filing Summary

IceCure Medical Ltd.’s Chief Financial Officer, Peleg Meir, filed an initial ownership report showing 400,000 restricted share units (RSUs) granted on May 17, 2026. Twenty-five percent vest on May 17, 2027, with the remaining 75% vesting in equal quarterly 6.25% installments, all unvested as of the grant date.

Insights

Equity compensation analyst

CFO receives 400,000 RSUs with multi-year vesting.

Peleg Meir, the CFO of IceCure Medical Ltd., reports beneficial ownership of 400,000 restricted share units. These RSUs were granted on May 17, 2026, indicating an equity-based compensation award rather than a market transaction.

The vesting schedule is back‑loaded: 25% vests on May 17, 2027, and the remaining 75% vests in equal quarterly installments of 6.25%. All units remain unvested as of the grant date, tying the CFO’s upside to continued service and future company performance over several years.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peleg Meir

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Ordinary shares	--	--	--

Holdings After Transaction: Ordinary shares — 400,000 shares (Direct)

Footnotes (1)

1. F1. Represents 400,000 restricted share units ("RSUs") granted on May 17, 2026, 25% of which vest on May 17, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of May 17, 2026.

Key Figures

RSU grant size: 400,000 RSUs Initial vesting tranche: 25% of RSUs Ongoing vesting rate: 6.25% quarterly

3 metrics

RSU grant size 400,000 RSUs Granted May 17, 2026 to CFO Peleg Meir

Initial vesting tranche 25% of RSUs Vests on May 17, 2027

Ongoing vesting rate 6.25% quarterly Remaining 75% of RSUs after first anniversary

Key Terms

restricted share units ("RSUs"), vest, quarterly installments

3 terms

restricted share units ("RSUs") financial

"Represents 400,000 restricted share units ("RSUs") granted on May 17, 2026"

vest financial

"25% of which vest on May 17, 2027 and the remaining 75% vest in equal quarterly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"the remaining 75% vest in equal quarterly installments of 6.25% thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did IceCure Medical (ICCM) CFO Peleg Meir report?

Peleg Meir reported beneficial ownership of 400,000 restricted share units (RSUs). These RSUs were granted on May 17, 2026 as part of his equity compensation, with all units unvested on the grant date according to the disclosure.

How do the 400,000 RSUs granted to IceCure Medical’s CFO vest?

The 400,000 RSUs vest over time. Twenty-five percent vest on May 17, 2027, and the remaining 75% vest in equal quarterly installments of 6.25%, creating a multi-year vesting schedule tied to continued service.

Were any of IceCure Medical CFO’s RSUs vested as of May 17, 2026?

No, all 400,000 restricted share units remained unvested as of May 17, 2026. The first vesting event occurs one year later, on May 17, 2027, followed by quarterly vesting for the remaining units.

Is IceCure Medical CFO’s RSU grant a market purchase or a compensation award?

The 400,000 units represent a restricted share unit compensation grant. The footnote describes them as RSUs granted on May 17, 2026, indicating an equity award rather than an open-market share purchase or sale.

What role does Peleg Meir hold at IceCure Medical (ICCM)?

Peleg Meir serves as Chief Financial Officer of IceCure Medical Ltd. The Form 3 filing identifies him as an officer with this title, and the RSU grant aligns with typical executive equity compensation structures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 08:00 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Peleg Meir

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/17/2026

3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	400,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 400,000 restricted share units ("RSUs") granted on May 17, 2026, 25% of which vest on May 17, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of May 17, 2026.

	/s/ Meir Peleg	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)